Navigation Links
Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action
Date:2/25/2011

ts statements or its pleadings that undermines the safety and efficacy of Auralgan as a treatment for ear pain and inflammation."

At this time the government's claims are only allegations in a legal proceeding.  Until a court makes a determination on this issue, it remains legally unresolved whether Auralgan qualifies as a "new drug" product.  

Recently, FDA has begun to take actions against classes of products that it believes should not be categorized as "old drugs" and instead should be regulated as "new drugs".  Unlike previous actions, FDA did not take action against both Auralgan and its generic substitutes, but instead, has solely focused its actions on Auralgan.  Currently, Auralgan represents 3% of the market for this class of drug products, with generic substitutes accounting for the other 97%.  FDA has not announced any action against any of these generic competitors or explained whether it intends to take any action against these products in the future.

History of Auralgan

Auralgan, is a solution of antipyrine and benzocaine and has been marketed in the United States since 1947 as a treatment for ear pain and inflammation associated with acute otitis media ("AOM").  

When Deston acquired the rights to Auralgan in 2006, this product and other generic equivalents had been marketed for over fifty years.  During this fifty year period, FDA had never taken enforcement action against any manufacturer for selling these types of drug products as unapproved "new drugs".  FDA's last official statement regarding the regulatory status of Auralgan occurred in 1981 when the Agency's Assistant to the Director, Division of Drug Labeling Compliance said that the Agency had not made a determination whether Auralgan qualified as a "new drug."

During this fifty year period of marketing, Auralgan was the subject of clinical trials supporting its use as safe and effective.  Additio
'/>"/>

SOURCE Deston Therapeutics LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014  Hanger, Inc. (NYSE: ... report its results of operations for the quarter ended ... the market closes.  A conference call to discuss these ... on Friday, November 7, 2014. Those wishing to participate ... Friday, November 14, 2014 by dialing 1-855-859-2056 and referencing ...
(Date:10/17/2014)... 2014 Research and Markets  has ... Development Prospect of China Dialysis Market, 2014-2018" ... on the 2013 version, this update Report provides ... industry and the relevant effect in recent three ... segmentations. Moreover, it analyzes Chinese private-owned hemodialysis services. ...
(Date:10/17/2014)... -- Investor-Edge has initiated coverage on the ... ), NPS Pharmaceuticals Inc. (NASDAQ: NPSP ), ... Inc. (NASDAQ: MNTA ), and Catalyst Pharmaceutical ... companies can be accessed at: http://investor-edge.com/register . ... ended on a mixed note as the Dow Jones ...
Breaking Medicine Technology:Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5
... & Gamble Company (NYSE: PG ) today announced ... Advisory Panel (SEAP). The new members are: ... Dr. Howard Frumkin – Dean, School of the Public ... Former Secretary, California Environmental Protection Agency ...
... 2011 Following through with plans to expand its Medical ... Florida. Currently operating on a fee for service basis, OMI ... the state. IMD Companies anticipates that OMI will be servicing ... of time. ABOUT IMD COMPANIES, INC. ...
Cached Medicine Technology:P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 2P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 3IMD Companies, Inc. Announces OMI Operations in Florida 2
(Date:10/20/2014)... 20, 2014 Do you ever feel ... comes a wonderful app Metassessor for teachers, specialists and ... helped its client “Intervention Development LLC” to launch ... is designed for iOS 4.3 or later and is ... is optimized for iPhone 5. It is now available ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
(Date:10/19/2014)... 2014 Visual Impact Frequency Training ... been released to the public generating a frenzied ... and fitness community. The commotion surrounding the program's ... Delmonico prompting an investigative review. , "Many gym-goers ... is commonly known as a training 'plateau' where ...
(Date:10/19/2014)... October 19, 2014 The federal ... continuing to move forward in Massachusetts federal court, ... filed over the dialysis medication, Bernstein Liebhard LLP ... October 15th shows 2,127 claims now filed over ... in the U.S. District Court, District of Massachusetts. ...
(Date:10/19/2014)... California (PRWEB) October 19, 2014 Theme and ... plugin for Final Cut Pro X entitled ProSketchy. ... looking text into any video project.” Said Christiana Austin, CEO ... needed to customize their own sketch style text.” , With ... smudged and smeared text all with in Final Cut Pro ...
Breaking Medicine News(10 mins):Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 3Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 4Health News:Announcing a New Plugin for Final Cut Pro X ProSketchy from Pixel Film Studios 2Health News:Announcing a New Plugin for Final Cut Pro X ProSketchy from Pixel Film Studios 3
... , ... ... , ... , , ...
... disease (HD) is a cruel, hereditary condition that leads to ... Currently, there are no treatments to slow down or ... although they do not show symptoms until late in life. ... of Neuroscience , Stephen Ferguson and Fabiola Ribeiro of Robarts ...
... ... supplements has created a brand new market for health supplements, customers who want to ... attention, HGH Supplements like Sytropin. , ... (PRWEB) February 23, 2010 -- Increased positive coverage by respected media ...
... , ... ... ... ...
... ... ... ... ...
... The George Washington University, School of Public Health and Health ... chronic disease, is on the rise in America and released ... surging cost of treatment, and the more than 1 million ... from GW, Changing pO2licy: The Elements for Improving Childhood Asthma ...
Cached Medicine News:Health News:Catholic Health Association Statement on February 25 Health Reform Summit 2Health News:Catholic Health Association Statement on February 25 Health Reform Summit 3Health News:Protecting the brain from a deadly genetic disease 2Health News:Sytropin HGH Shows Promising Anti-Aging Results 2Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 2Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 3Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 4Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 5Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 2Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 3Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 4Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 5Health News:Startling new childhood asthma data 2Health News:Startling new childhood asthma data 3Health News:Startling new childhood asthma data 4
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 24 gage needle stick is desired....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Medicine Products: